Open AccessACE2 polymorphism and susceptibility for SARS-CoV-2 infection and severity of COVID-19
Author(s) -
Birte Möhlendick,
Kristina Schönfelder,
Katharina Breuckmann,
Carina Elsner,
Nina Babel,
Paul Balfanz,
Edgar Dahl,
Michael Dreher,
David Fistera,
Frank Herbstreit,
Bodo Hölzer,
Michael Koch,
Matthias Kohnle,
Nikolaus Marx,
Joachim Riße,
Karsten Schmidt,
Sarah Skrzypczyk,
Sivagurunathan Sutharsan,
Christian Taube,
Timm H. Westhoff,
KarlHeinz Jöckel,
Ulf Dittmer,
Winfried Siffert,
Andreas Kribben
Publication year - 2021
Publication title -
pharmacogenetics and genomics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.579
H-Index - 140
eISSN - 1744-6880
pISSN - 1744-6872
DOI - 10.1097/fpc.0000000000000436
Subject(s) - single nucleotide polymorphism , genotyping , genotype , coronavirus , disease , immunology , medicine , virology , biology , covid-19 , gene , genetics , infectious disease (medical specialty)
The RNA virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for coronavirus disease 2019 (COVID-19). Cell entry is mediated by the human angiotensin-converting enzyme II (ACE2). ACE2 and its close homolog angiotensin-converting enzyme I (ACE) are currently discussed candidate genes, in which single-nucleotide polymorphisms (SNPs) could alter binding or entry of SARS-CoV-2 and enhance tissue damage in the lung or other organs. This could increase the susceptibility for SARS-CoV-2 infection and the severity of COVID-19.